Business Context and Reporting Period
This Form 8-K Current Report was filed by Oncobiologics, Inc. (not Outlook Therapeutics, Inc.) on March 27, 2018, covering events occurring on March 23, 2018. The registrant is a Delaware corporation and an emerging growth company. The filing primarily addresses changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance rather than financial performance.
Material Changes
- Resignation: Yezan Haddadin resigned as a Class II director and member of the Audit Committee effective March 23, 2018. The resignation was not due to any disagreement with the Board or the Company.
- Appointment: Joerg Windisch, Ph.D., was appointed as a Class II director to fill the vacancy created by Mr. Haddadin's departure. His term lasts until the 2018 Annual Meeting of Stockholders or until a successor is elected.
- Committee Reassignments: Dr. Windisch was appointed to the Compensation Committee. Mr. Thomas was appointed to the Audit Committee, replacing Dr. Windisch.
- Contractual Basis: Dr. Windisch's appointment was made pursuant to an Investor Rights Agreement dated September 11, 2017, with GMS Tenshi Holdings Pte. Limited, granting them rights to appoint directors based on ownership percentage.
Compensation and Governance Details
Dr. Windisch's compensation includes:
- Annual Retainer: $35,000 for director services and $5,000 for Compensation Committee service, payable in quarterly installments in arrears.
- Stock Option Grant: An option to purchase 25,000 shares of common stock granted on March 23, 2018.
- Vesting Schedule: 33.33% vests on the first, second, and third anniversaries of the grant date, with 100% vesting on the four-year anniversary, subject to continued service.
Investor Verification Checklist
- Verify the correct registrant name is Oncobiologics, Inc., not Outlook Therapeutics, Inc.
- Confirm the terms of the Investor Rights Agreement with GMS Tenshi Holdings Pte. Limited regarding director appointment rights.
- Review the Company's non-employee director compensation policy adopted in January 2016 for full details on retainer structures.
- Check the Company's 2018 Annual Meeting of Stockholders schedule to determine the exact end date of Dr. Windisch's interim term.